Table 1.

Patient demographics, pathological and oncological outcomes of the reTUR and no reTUR groups.

Variable	ReTUR	No reTUR	P
Number of patients	50	56
Patient demographics
Age, years, median (IQR)	74 (70.25–78)	76 (69–82.25)	0.43
Sex, n (%)
Male	33 (66)	43 (77)	0.28
Female	17 (34)	13 (23)
History of UTUC, n (%)	6 (12)	6 (11)	1
Recurrent tumours, n (%)	6 (12)	10 (18)	0.43
Positive cytology, n (%)	14 (28)	9 (20)	0.34
Multiple tumours, n (%)	25 (50)	27 (48)	1
Non‐papillary tumours, n (%)	8 (16)	7 (12)	0.78
Sessile tumours, n (%)	21 (42)	17 (30)	0.23
Tumour diameter, mm, mean (SD)	20.6 (9.7)	20.8 (10.9)	0.93
Number of tumours, mean (SD)	2.22 (2.26)	2.16 (1.91)	0.88
Pathological diagnosis at initial ERBT
Concomitant CIS, n (%)	22 (44)	15 (27)	0.07
Adequate sampling of MP, n (%)	47 (94)	52 (93)	1
pT1a/b sub‐staging, n (%)
pT1a	36 (72)	38 (68)	0.68
pT1b	14 (28)	18 (32)
Positive horizontal margin, n (%)	21 (42)	15 (37)	0.52
Positive vertical margin, n (%)	4 (8)	3 (5.4)	1
Pathological diagnosis at repeat resection
Residual pTa/is	6 (12)	‐
Residual pT1	3 (6)	‐
Upstaging to pT2	0	‐
Treatment and oncological outcomes
Immediate bladder instillation therapy, n (%)	33 (66)	42 (75)	0.39
Maintenance bladder instillation therapy, n (%)	36 (72)	30 (54)	0.07
Follow‐up, months, median (IQR)	23 (13–35)	22.5 (11.75–42.25)	0.79
Recurrence, n (%)	18 (36)	18 (32)	0.68
Progression, n (%)	7 (14)	6 (11)	0.77
2‐year RFS, % (95% CI)	55.1 (37.2–69.8)	59.9 (43.1–73.2)	0.55
3‐year PFS, % (95% CI)	80.6 (59.5–91.4)	82.6 (63.7–92.2)	0.64

UTUC, upper urinary tract urothelial carcinoma.